Dipexium Pharmaceuticals: General Instruction A.2. Below)

The following excerpt is from the company's SEC filing.

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Item 5.07.  Submission of Matters to a Vote of Security Holders.

On May 15, 2015, Dipexium Pharmaceuticals, Inc. (the “Company”) held its 2015 Annual Meeting of Stockholders (the “Annual Meeting). Of the 8,564,675 shares of the Company’s common stock outstanding and eligible to vote at the Annual Meeting, 7,117,459 shares, or 83.1% of the eligible common stock, were present either in person or by proxy.  The final results of the matters voted on at the Annual Meeting are provided below.

Proposal 1

: The following individuals were elected as directors to hold office for the term that expires at the 2016 Annual Meeting of Stockholders for each director, or until their respective successors are elected and qualified, or until such directors earlier resignation or removal:

Director Name

Withheld

Broker

Non-Votes

Abstained

Robert J. DeLuccia

6,072,041

30,047

1,015,371

David P. Luci

6,072,541

29,547

Jack H. Dean

5,889,450

212,638

Michael Duffy

6,068,425

33,663

Thomas Harrison

6,076,488

25,600

William J. McSherry, Jr.

6,072,387

29,701

Barry Kagan

6,075,988

26,100

Proposal 2

: An amendment to the Company’s 2013 Equity Incentive Plan increasing the shares of our common stock available for issuance thereunder by 433,594 shares from 1,707,575 to 2,141,169  was approved.

6,020,011

Against:

81,350

Abstained:

Broker Non-Votes:

Proposal 3

: A non-binding resolution regarding named executive officer compensation was approved.

Proposal 4

: To cast an advisory vote on the frequency of future executive compensation advisory votes.

1 year:

1,144,262

2 years:

15,664

3 years

4,924,532

17,630

With respect to proposal 4, the non-binding advisory vote on the frequency of future executive compensation advisory votes, approximately 80.7% of the votes cast voted in favor of holding the advisory vote every 3 years.  In light of such vote, the Board has determined that the Company will include a shareholder advisory vote on the compensation of executive officers in its proxy materials every 3 years from the 2015 Annual Shareholders meeting.

Proposal 5

: CohnReznick, LLP was ratified as the Company’s Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2015.

7,097,036

12,401

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 19, 2015

DIPEXIUM PHARMACEUTICALS, INC.

/s/ David P. Luci

Name: 

David P. Luci

Title: 

President and Chief Executive Officer

The above information was disclosed in a filing to the SEC. To see this filing in its entirety, click here.

To receive a free e-mail notification whenever Dipexium Pharmaceuticals, Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

Dipexium Pharmaceuticals: Plx Pharma Hires Key Commercial Executives In Preparation For Future Launch Of Aspertec - Sept. 19, 2017

Auto Refresh

Feedback